Literature DB >> 10862121

Gas chromatography/negative ion chemical ionization mass spectrometry and liquid chromatography/electrospray ionization tandem mass spectrometry quantitative profiling of N-acetylcysteine conjugates of valproic acid in urine: application in drug metabolism studies in humans.

S V Gopaul1, K Farrell, F S Abbott.   

Abstract

We report a GC/NICI-MS assay and a LC/ESI-MS/MS assay for the analysis of N-acetylcysteine (NAC) conjugates of (E)-2,4-diene VPA (NAC I and NAC II) identified in humans. The assay also includes the analysis of the NAC conjugate of 4,5-epoxy VPA (NAC III), an identified metabolite in rats treated with 4-ene VPA for its use in metabolic studies in animals. The highly sensitive GC/MS assay was designed to monitor selectively the diagnostic and most abundant [M - 181](-) fragment anion of the di-PFB derivatives of NAC I, NAC II, and NAC IV, the internal standard (IS) and the PFB derivative of NAC III. The higher selectivity of LC/MS/MS methodology was the basis for an assay which could identify and quantitate the underivatized conjugates simultaneously using MRM of the diagnostic ions m/z 130 and 123 arising from the CID of their protonated molecular ions [MH](+). The GC/MS assay employed liquid-liquid extraction whereas the LC/MS/MS assay used a solid-phase extraction procedure. Linearity ranges of the calibration curves were 0.10-5.0microg ml(-1) by GC/MS and 0.10-1.0microg ml(-1) by LC/MS/MS for NAC I, NAC II and NAC III (r(2) = 0.999 or better). Both assays were validated for NAC I and NAC II and provided good inter- and intra-assay precision and accuracy for NAC I and NAC II. The LOQ by LC/MS/MS was 0.1microg ml(-1), representing 1 ng of NAC I and NAC II. The same LOQ (0.1microg ml(-1)) was observed by GC/MS and was equivalent to 100 pg of each metabolite. NAC III was detected at concentrations as low as 0.01 microg ml(-1) by both methods. The total urinary excretion of the NAC conjugates in four patients on VPA therapy was determined to be 0.004-0.088% of a VPA dose by GC/MS and 0.004-0. 109% of a VPA dose by LC/MS/MS. Copyright 2000 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10862121     DOI: 10.1002/1096-9888(200006)35:6<698::AID-JMS996>3.0.CO;2-S

Source DB:  PubMed          Journal:  J Mass Spectrom        ISSN: 1076-5174            Impact factor:   1.982


  4 in total

Review 1.  Identifying genomic and developmental causes of adverse drug reactions in children.

Authors:  Mara L Becker; J Steven Leeder
Journal:  Pharmacogenomics       Date:  2010-11       Impact factor: 2.533

2.  Rapid detection and identification of N-acetyl-L-cysteine thioethers using constant neutral loss and theoretical multiple reaction monitoring combined with enhanced product-ion scans on a linear ion trap mass spectrometer.

Authors:  Karoline Scholz; Wolfgang Dekant; Wolfgang Völkel; Axel Pähler
Journal:  J Am Soc Mass Spectrom       Date:  2005-10-24       Impact factor: 3.109

3.  Effects of valproic acid on organic acid metabolism in children: a metabolic profiling study.

Authors:  K E Price; R E Pearce; U C Garg; B A Heese; L D Smith; J E Sullivan; M J Kennedy; J F Bale; R M Ward; T K H Chang; F S Abbott; J S Leeder
Journal:  Clin Pharmacol Ther       Date:  2011-05-04       Impact factor: 6.875

4.  Single valproic acid treatment inhibits glycogen and RNA ribose turnover while disrupting glucose-derived cholesterol synthesis in liver as revealed by the [U-C(6)]-d-glucose tracer in mice.

Authors:  Richard D Beger; Deborah K Hansen; Laura K Schnackenberg; Brandie M Cross; Javad J Fatollahi; F Tracy Lagunero; Zoltan Sarnyai; Laszlo G Boros
Journal:  Metabolomics       Date:  2009-03-31       Impact factor: 4.290

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.